SecBot SecBot
424B5 ·Filed Jun 9, 2026

IDYA

IDEAYA Biosciences, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago SEC0001193125-26-264032
Notable filing: 424B5
Actionable Insight ▼ Bearish

The 14.2% discount to market and immediate dilution of $13.95 per share signal near-term selling pressure. Monitor for potential further equity raises given the company's pre-commercial status and broad discretion over proceeds. The underwriters' 30-day option for additional shares adds overhang. Watch for any clinical catalysts (darovasertib NDA filing in H2 2026) that could offset dilution concerns.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$27.60
T+0 close · Jun 9, 2026 · via day close
Latest settled
+44.82%
T+60 · $39.97
Vs SPY
+38.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 10 $27.60entry
  2. T+1 · 5mo ago +4.49%α +2.79% · $28.84
  3. T+5 · 5mo ago +10.76%α +7.33% · $30.57
  4. T+20 · 4mo ago +35.07%α +31.45% · $37.28
  5. T+60 · 2mo ago +44.82%α +38.24% · $39.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, priced at $27.00 per share (and $26.9999 per pre-funded warrant). The offering represents roughly 6.3% dilution to existing shareholders based on shares outstanding as of March 31, 2026, and was priced at a 14.2% discount to the last closing price of $31.48. Proceeds will fund continued clinical development and potential commercialization of darovasertib for uveal melanoma, pipeline advancement, and general corporate purposes.

Key Facts

  • Offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares at $27.00 per share/$26.9999 per warrant
  • Net proceeds of approximately $281.3 million ($323.6 million if underwriters' option exercised in full)
  • Priced at a 14.2% discount to the $31.48 closing price on June 8, 2026
  • Immediate dilution of $13.95 per share to new investors; as-adjusted net tangible book value increases from $10.67 to $13.05 per share
  • Underwriters have a 30-day option to purchase up to 1,666,669 additional shares
  • Proceeds to fund darovasertib development, pipeline advancement, and general corporate purposes
  • Lock-up agreements with directors and executive officers for 60 days post-offering

Financial Impact

~$300M gross offering; ~$282M net proceeds; ~6.3% dilution to existing shareholders based on 87.9M shares outstanding pre-offering

dilutioncashPositionbookValue

Risk Factors

  • Immediate and substantial dilution to existing shareholders ($13.95 per share)
  • Potential for further equity offerings given pre-revenue status and broad capital needs
  • Underwriters' option for additional shares creates near-term overhang
  • No guarantee that proceeds will enhance shareholder value given management's broad discretion
  • Stock price volatility common in biotechnology sector

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-264032
Document: d160204dexfilingfees.htm0001193125-26-264032
Document: 0001193125-26-264032-index-headers.html0001193125-26-264032
Document: 0001193125-26-264032-index.html0001193125-26-264032
Document: 0001193125-26-264032.txt0001193125-26-264032

Track record

13 reports on IDYA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Viewing Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (11h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026